Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making
Executive Summary
The strong, continued resistance by FDA Center for Drug Evaluation and Research officials to rely on meta-analyses and observational studies as the basis for removing Avandia from the market suggests it will take time for the agency to become comfortable using the active surveillance system envisioned under the Sentinel Initiative in regulatory decision-making.
You may also be interested in...
FDA Seeks Dedicated Meta-Analysis Team As Part Of PDUFA V User Fee Funding
FDA wants to create a meta-analysis team to conduct its own studies with funding from the next round of application user fees.
FDA Seeks Dedicated Meta-Analysis Team As Part Of PDUFA V User Fee Funding
FDA wants to create a meta-analysis team to conduct its own studies with funding from the next round of application user fees.
FDA Finds “Comfort Level” With Using Medicare Data For Sentinel Initiative
FDA research into the clinical accuracy and stability over time of Medicare claims data has shown it could be a reliable source of information for active product safety surveillance, according to FDA’s Judy Racoosin, scientific lead for the Sentinel Initiative within the Center for Drug Evaluation and Research.